URODELIA has developed a personalized therapeutic treatment combining proteins from tumor cells with hydroxyapatite. Based on the results obtained in spontaneous cancers in animals, URODELIA is now entering a decisive phase: the development of its personalized immunotherapy in human oncology.

Today URODELIA is on the threshold of a new stage of its development: the implementation of a program of clinical studies on its personalized immunotherapy to confirm in humans the first conclusions obtained in animals:

• Confirmation of the efficiency of its concept for humans and human medicine.
• Validation of the same total safety of the treatment in humans as in pets.